Updated Jul 16, 2026
Rangwala Reshma has filed 2 SEC Form 4 filings across 1 company in the last 90 days — selling. Lifetime open-market sales: $58K.
Reshma Rangwala is the Executive Vice President and Chief Medical Officer at Karyopharm Therapeutics Inc., a company focused on developing novel cancer therapies. She has been involved in the pharmaceutical industry, particularly in roles related to drug development and clinical research.
| Role | Insider |
|---|---|
| Notability | 20/100 |
| Date | Ticker | Company | Code | Shares | Price | Value |
|---|---|---|---|---|---|---|
| 2026-05-15 | KPTI | Karyopharm Therapeutics Inc. | S — Open-market sale | 408 | $9.50 | $4K |
| 2026-05-15 | KPTI | Karyopharm Therapeutics Inc. | A — Grant or award | 947 | $0.00 | |
| 2026-04-22 | KPTI | Karyopharm Therapeutics Inc. | S — Open-market sale | 449 | $8.94 | $4K |
| 2026-03-03 | KPTI | Karyopharm Therapeutics Inc. | S — Open-market sale | 5.1K | $9.41 | $48K |
| 2026-02-03 | KPTI | Karyopharm Therapeutics Inc. | A — Grant or award | 32.4K | $0.00 | |
| 2025-09-12 | KPTI | Karyopharm Therapeutics Inc. | S — Open-market sale | 408 | $6.43 | $3K |
| 2025-09-12 | KPTI | Karyopharm Therapeutics Inc. | A — Grant or award | 945 | $0.00 |
Reshma Rangwala is the Executive Vice President and Chief Medical Officer at Karyopharm Therapeutics Inc., a company focused on developing novel cancer therapies. She has been involved in the pharmaceutical industry, particularly in roles related to drug development and clinical research.…
2 primary Form 4 filings in the last 90 days, covering 1 company.
Recorded transactions: 0 open-market purchases () and 4 open-market sales ($58K) across all tracked filings.
All Form 4 filings, transaction values, and 10b5-1 plan flags are listed on this page and updated in real time as new SEC EDGAR filings are processed.
Open the live Rangwala Reshma profile on InsiderAlpha for real-time alerts, AI-scored trade ideas, and full transaction history.